FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2772916863> ?p ?o ?g. }

• W2772916863 endingPage "4702" @default.
• W2772916863 startingPage "4702" @default.
• W2772916863 abstract "Purpose: This work is aimed at determining the efficacy of the novel clinical stage mitotic inhibitor ON 01910.Na in HNC, and to elucidate gene expression-based predictors of efficacy, in comparison with approved therapeutic agents. We used a rational pathway-driven comparison of global gene expression (Affymetrix U133) to correlate changes in expression with efficacy. Methods: We used 29 HNC cell lines and tested ON 01910.Na and a panel of 10 approved agents (including cetuximab, erlotinib, docetaxel and bortezomib). We then correlated the antitumor efficacy with gene expression profiles of these cell lines, using unbiased gene set expression analysis (GSEA; www.broad.mit.edu/gsea/) of 198 pathways. GSEA permits elucidating modest but coordinated gene expression differences at the pathway level. Results: We obtained a mosaic of susceptibilities in the panel. At clinically relevant concentrations (1 uM) docetaxel, bortezomib and ON 01910.Na significantly inhibited growth in 27, 27, and 25 cell lines respectively, whereas only 9 were inhibited with erlotinib and only two by cetuximab. Expression analysis for ON 01910.Na indicated that at 0.1 microM, the #8220;cell cycle pathway#8221; was the tenth most expressed gene set in comparing the sensitive vs resistant cell lines, whereas the #8220;p53 pathway#8221; was the most highly expressed in resistant vs sensitive strains. At 1 uM, the #8220;cell cycle#8221; pathway was the most differentially expressed pathway in comparing sensitive vs resistant cell lines. Of the 98 genes in the #8220;cell cycle#8221; pathway, those acting as #8220;driver#8221; genes included CHEK1, CCNE2, CDC6, CDC7, SMAD4, and CCND2. The analysis of bortezomib showed that the #8220;proteasome#8221; pathway was the fifth most expressed of 198 pathways in sensitive vs resistant. Similar analysis with docetaxel indicated that pathways over-expressing cytoskeleton components were particularly expressed in sensitive strains. Conclusions: ON 01910.Na is a highly effective mitotic inhibitor active in a broad panel of HNC cell lines, with potentcy equivalent or superior to approved agents. Expression analysis revealed that sensitive strains had over-expression of the cell cycle pathway (providing further evidence of mechanisms relevant in the action of ON 01910.Na in HNC). The only four resistant cell lines shared over-expression of the p53 pathway as the leading expression alteration. The #8220;cell cycle#8221; pathway changes were drug dose dependent. Overall this suggests that cells with a de-regulated cell cycle are more sensitive to ON 01910, and that a functional p53 pathway dictates resistance. These results combined with the observations with established therapeutic agents suggest that pathway comparisons provide a rational method for identifying targets for new drugs and biomarkers for personalized therapy. Complete pathway expression profiles for all drugs tested and in vivo data will be presented. Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4702." @default.
• W2772916863 created "2017-12-22" @default.
• W2772916863 creator A5000883249 @default.
• W2772916863 creator A5007992309 @default.
• W2772916863 creator A5058849373 @default.
• W2772916863 creator A5064136404 @default.
• W2772916863 creator A5080301921 @default.
• W2772916863 date "2009-05-01" @default.
• W2772916863 modified "2023-09-23" @default.
• W2772916863 title "Abstract #4702: Pathway-based comparison approach for the identification of responders to the mitotic modulator ON 01910.Na in head and neck cancer (HNC)" @default.
• W2772916863 hasPublicationYear "2009" @default.
• W2772916863 type Work @default.
• W2772916863 sameAs 2772916863 @default.
• W2772916863 citedByCount "0" @default.
• W2772916863 crossrefType "journal-article" @default.
• W2772916863 hasAuthorship W2772916863A5000883249 @default.
• W2772916863 hasAuthorship W2772916863A5007992309 @default.
• W2772916863 hasAuthorship W2772916863A5058849373 @default.
• W2772916863 hasAuthorship W2772916863A5064136404 @default.
• W2772916863 hasAuthorship W2772916863A5080301921 @default.
• W2772916863 hasConcept C104317684 @default.
• W2772916863 hasConcept C121608353 @default.
• W2772916863 hasConcept C1491633281 @default.
• W2772916863 hasConcept C150194340 @default.
• W2772916863 hasConcept C203014093 @default.
• W2772916863 hasConcept C2776364478 @default.
• W2772916863 hasConcept C2777478702 @default.
• W2772916863 hasConcept C2778087573 @default.
• W2772916863 hasConcept C2779438470 @default.
• W2772916863 hasConcept C2779998722 @default.
• W2772916863 hasConcept C2781190966 @default.
• W2772916863 hasConcept C29537977 @default.
• W2772916863 hasConcept C502942594 @default.
• W2772916863 hasConcept C526805850 @default.
• W2772916863 hasConcept C54355233 @default.
• W2772916863 hasConcept C81885089 @default.
• W2772916863 hasConcept C86803240 @default.
• W2772916863 hasConceptScore W2772916863C104317684 @default.
• W2772916863 hasConceptScore W2772916863C121608353 @default.
• W2772916863 hasConceptScore W2772916863C1491633281 @default.
• W2772916863 hasConceptScore W2772916863C150194340 @default.
• W2772916863 hasConceptScore W2772916863C203014093 @default.
• W2772916863 hasConceptScore W2772916863C2776364478 @default.
• W2772916863 hasConceptScore W2772916863C2777478702 @default.
• W2772916863 hasConceptScore W2772916863C2778087573 @default.
• W2772916863 hasConceptScore W2772916863C2779438470 @default.
• W2772916863 hasConceptScore W2772916863C2779998722 @default.
• W2772916863 hasConceptScore W2772916863C2781190966 @default.
• W2772916863 hasConceptScore W2772916863C29537977 @default.
• W2772916863 hasConceptScore W2772916863C502942594 @default.
• W2772916863 hasConceptScore W2772916863C526805850 @default.
• W2772916863 hasConceptScore W2772916863C54355233 @default.
• W2772916863 hasConceptScore W2772916863C81885089 @default.
• W2772916863 hasConceptScore W2772916863C86803240 @default.
• W2772916863 hasLocation W27729168631 @default.
• W2772916863 hasOpenAccess W2772916863 @default.
• W2772916863 hasPrimaryLocation W27729168631 @default.
• W2772916863 hasRelatedWork W1968080394 @default.
• W2772916863 hasRelatedWork W1990451849 @default.
• W2772916863 hasRelatedWork W2007052564 @default.
• W2772916863 hasRelatedWork W2011944933 @default.
• W2772916863 hasRelatedWork W2022219037 @default.
• W2772916863 hasRelatedWork W2052831589 @default.
• W2772916863 hasRelatedWork W2085967502 @default.
• W2772916863 hasRelatedWork W2091852911 @default.
• W2772916863 hasRelatedWork W2099516828 @default.
• W2772916863 hasRelatedWork W2316386727 @default.
• W2772916863 hasRelatedWork W2319504853 @default.
• W2772916863 hasRelatedWork W2325727965 @default.
• W2772916863 hasRelatedWork W2335355374 @default.
• W2772916863 hasRelatedWork W2557392219 @default.
• W2772916863 hasRelatedWork W2563735239 @default.
• W2772916863 hasRelatedWork W2586449045 @default.
• W2772916863 hasRelatedWork W2734339504 @default.
• W2772916863 hasRelatedWork W2915924992 @default.
• W2772916863 hasRelatedWork W2955172389 @default.
• W2772916863 hasRelatedWork W3181696480 @default.
• W2772916863 hasVolume "69" @default.
• W2772916863 isParatext "false" @default.
• W2772916863 isRetracted "false" @default.
• W2772916863 magId "2772916863" @default.
• W2772916863 workType "article" @default.